US distribution will be handled by Vitruvias and Bright Future will be responsible for China and other agreed upon Asian territories.
The products will be manufactured by Bright Future's newly constructed unit at its Hong Kong site specifically designed for producing products in regulated markets.
Vitruvias Therapeutics is a generic pharmaceutical company which utilises domestic and international partnerships to develop, manufacture, and market generic products.
Founded in the southern US in 2013, the company's primary focus is on products in the generic sterile injectable market, semi-solid market, and selected high-value oral solids.
The company currently markets several generic products in the US The company received its first approval in September 2017 and anticipates several additional ANDA applications will be filed during 2019.
Headquartered in Hong Kong, Bright Future Group is a leading pharmaceutical company committed to developing generic medical solutions since 1993.
Currently, the company is the largest PIC/S GMP certified pharmaceutical manufacturer in Hong Kong.
With years of development, it has also established subsidiary plants in Hong Kong, Mainland China, the USA and Germany.
Pursuing its long-term corporate vision, 7,000 employees dedicate themselves to the research and development, manufacturing and commercialization of generic medicines, health supplements and daily necessities worldwide.
It focuses on the treatment of disorders for patients in the areas of dermatology, orthopedics, respiratory, pediatrics, geriatric and gynecology.
Bright Future Group has international R and D teams in Hong Kong, New York, as well as Haikou and Suzhou in China to support its network.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review